Company intelligence / Profile preview

MacuSight

Union City, California, United Statesbiospace.com ↗

Ownership: Private
Development stage: Phase 1

Overview

MacuSight developed a proprietary formulation of sirolimus (rapamycin) for ocular diseases. The company completed Phase I trials for DME and was initiating Phase II trials for DME and wet AMD as of 2008-2009. The drug demonstrated multiple mechanisms of action including immunosuppressive, anti-angiogenic, anti-migratory, anti-proliferative, anti-fibrotic and anti-permeability activity.

Therapeutic areas: Ophthalmology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

sirolimus

Phase 1

Indications: Diabetic macular edema, Wet age-related macular degeneration

Partnerships

Santen Pharmaceutical (licensed rights for Japan and Asia for $50 million in 2008)

Beyond the preview

Go deeper on MacuSight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MacuSight.

Explore the full profile